$3.94
0.25% yesterday
Nasdaq, Oct 31, 09:00 pm CET
ISIN
US83558L1052
Symbol
SNOA

Sonoma Pharmaceuticals, Inc. Stock price

$3.94
+0.06 1.55% 1M
+0.14 3.68% 6M
+1.25 46.47% YTD
+1.26 47.01% 1Y
-35.86 90.10% 3Y
-145.72 97.37% 5Y
-1,130.06 99.65% 10Y
-49,136.06 99.99% 20Y
Nasdaq, Closing price Fri, Oct 31 2025
-0.01 0.25%
ISIN
US83558L1052
Symbol
SNOA
Industry

Key metrics

Basic
Market capitalization
$6.5m
Enterprise Value
$3.1m
Net debt
positive
Cash
$3.6m
Shares outstanding
1.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
0.4 | 0.4
EV/Sales
0.2 | 0.2
EV/FCF
negative
P/B
1.6
Financial Health
Equity Ratio
32.2%
Return on Equity
-78.4%
ROCE
-37.3%
ROIC
-49.9%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$14.9m | $17.6m
EBITDA
$-3.5m | -
EBIT
$-3.6m | $-2.8m
Net Income
$-3.6m | $-2.2m
Free Cash Flow
$-1.4m
Growth (TTM | estimate)
Revenue
17.4% | 23.0%
EBITDA
21.7% | -
EBIT
21.7% | 23.6%
Net Income
21.9% | 36.4%
Free Cash Flow
55.7%
Margin (TTM | estimate)
Gross
37.7%
EBITDA
-23.5% | -
EBIT
-24.4%
Net
-23.8% | -12.5%
Free Cash Flow
-9.2%
More
EPS
$-2.2
FCF per Share
$-0.8
Short interest
3.7%
Employees
10
Rev per Employee
$1.4m
Show more

Is Sonoma Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,030 stocks worldwide.

Sonoma Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Sonoma Pharmaceuticals, Inc. forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Sonoma Pharmaceuticals, Inc. forecast:

Buy
86%
Hold
14%

Financial data from Sonoma Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
15 15
17% 17%
100%
- Direct Costs 9.29 9.29
19% 19%
62%
5.62 5.62
15% 15%
38%
- Selling and Administrative Expenses 7.32 7.32
2% 2%
49%
- Research and Development Expense 1.94 1.94
4% 4%
13%
-3.50 -3.50
22% 22%
-23%
- Depreciation and Amortization 0.14 0.14
18% 18%
1%
EBIT (Operating Income) EBIT -3.63 -3.63
22% 22%
-24%
Net Profit -3.56 -3.56
22% 22%
-24%

In millions USD.

Don't miss a Thing! We will send you all news about Sonoma Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Sonoma Pharmaceuticals, Inc. Stock News

Neutral
Accesswire
18 days ago
BOULDER, CO / ACCESS Newswire / October 14, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader in developing and producing stabilized hypochlorous acid (HOCl) products based on its patented Microcyn® technology, today announced the launch of a new HOCl wound cleanser manufactured by Sonoma for Medline Industries, LP. The product will be distributed by Medline into hos...
Neutral
Accesswire
25 days ago
BOULDER, COLORADO / ACCESS Newswire / October 7, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypochlorous acid (HOCl) products, today announced that it has successfully registered its manufacturing facility and listed its Microcyn-based facial spray under the FDA's Modernization of Cosmetic...
Neutral
Accesswire
about one month ago
BOULDER, COLORADO / ACCESS Newswire / September 25, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, dermatological conditions, podiatry, and animal health care, today announced that it will parti...
More Sonoma Pharmaceuticals, Inc. News

Company Profile

Sonoma Pharmaceuticals, Inc. engages in identifying, developing, and commercializing therapies for chronic skin conditions. The company offers solutions in dermatology, animal healthcare, and advanced tissue care product areas. Its products target skin diseases including acne, atopic dermatitis, scarring, infections, itch, pain, and harmful inflammatory responses. The company was founded by Hojabr Alimi and Linda Alimi in April 1999 and is headquartered in Petaluma, CA.

Head office United States
CEO Amy Trombly
Employees 10
Founded 1999
Website sonomapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today